Literature DB >> 25749461

Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.

Priti Kambli1, Kanchan Ajbani1, Meeta Sadani1, Chaitali Nikam1, Anjali Shetty1, Zarir Udwadia2, Sophia B Georghiou3, Timothy C Rodwell3, Antonino Catanzaro3, Camilla Rodrigues4.   

Abstract

This study correlates MICs of rifampicin (RIF) and isoniazid (INH) with GenoType MTBDRplus assay results for drug-resistant Mycobacterium tuberculosis (MTB) clinical isolates. MICs of RIF and INH were established for 84 and 90 isolates, respectively, testing 7 concentrations of each drug. Genotypic resistance to each drug was determined by GenoType MTBDRplus assay with 50 representative mutations confirmed by pyrosequencing, with mutations in the rpoB gene associated with RIF resistance and mutations in the katG and/or inhA genes associated with INH resistance. Based upon the correlation of MICs with specific genetic profiles, relative resistance levels were established for each isolate. Results indicate that MTB phenotypic resistance, currently based upon the testing of isolate susceptibility to a single drug concentration, may be more accurately profiled via quantitative MICs, and therefore, the correlation of molecular diagnostic results with specific MICs may allow for more optimal treatment of infections.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug susceptibility testing; Level of resistance; Multidrug-resistant tuberculosis; Mutations

Mesh:

Substances:

Year:  2015        PMID: 25749461      PMCID: PMC4414878          DOI: 10.1016/j.diagmicrobio.2015.01.009

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

1.  Totally drug-resistant tuberculosis in India.

Authors:  Zarir F Udwadia; Rohit A Amale; Kanchan K Ajbani; Camilla Rodrigues
Journal:  Clin Infect Dis       Date:  2011-12-21       Impact factor: 9.079

2.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

3.  Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.

Authors:  Hongling Guo; Qihui Seet; Steven Denkin; Linda Parsons; Ying Zhang
Journal:  J Med Microbiol       Date:  2006-11       Impact factor: 2.472

4.  Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

Authors:  Ali Akbar Velayati; Mohammad Reza Masjedi; Parissa Farnia; Payam Tabarsi; Jalladein Ghanavi; Abol Hassan ZiaZarifi; Sven Eric Hoffner
Journal:  Chest       Date:  2009-04-06       Impact factor: 9.410

5.  Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.

Authors:  Burkhard Springer; Romana C Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2008-10-15       Impact factor: 5.948

Review 6.  Molecular diagnosis of tuberculosis and drug resistance.

Authors:  Shou-Yean Grace Lin; Edward P Desmond
Journal:  Clin Lab Med       Date:  2014-06       Impact factor: 1.935

7.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

8.  Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments.

Authors:  Kanchan Ajbani; Chaitali Nikam; Mubin Kazi; Christen Gray; Catharina Boehme; Kavita Balan; Anjali Shetty; Camilla Rodrigues
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa.

Authors:  N Sarita Shah; Jessica Richardson; Prashini Moodley; Salona Moodley; Palav Babaria; Melissa Ramtahal; Scott K Heysell; Xuan Li; Anthony P Moll; Gerald Friedland; A Willem Sturm; Neel R Gandhi
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

10.  The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.

Authors:  Frederick A Sirgel; Robin M Warren; Erik C Böttger; Marisa Klopper; Thomas C Victor; Paul D van Helden
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more
  12 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.

Authors:  Sophia B Georghiou; Marva Seifert; Donald G Catanzaro; Richard S Garfein; Timothy C Rodwell
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

3.  Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Authors:  S B Georghiou; M Seifert; D Catanzaro; R S Garfein; F Valafar; V Crudu; C Rodrigues; T C Victor; A Catanzaro; T C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

4.  Comparison of TaqMan(®) Array Card and MYCOTB(TM) with conventional phenotypic susceptibility testing in MDR-TB.

Authors:  S Foongladda; S Banu; S Pholwat; J Gratz; S O-Thong; N Nakkerd; R Chinli; S S Ferdous; S M M Rahman; A Rahman; S Ahmed; S Heysell; M Sariko; G Kibiki; E Houpt
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

5.  Clinical implications of discrepant results between genotypic MTBDRplus and phenotypic Löwenstein-Jensen method for isoniazid or rifampicin drug susceptibility tests in tuberculosis patients.

Authors:  Ji Young Kang; Jung Hur; Shinyoung Kim; Sanghoon Jeon; Jaeha Lee; Youn Jeong Kim; Seok Chan Kim; Yeon Joon Park; Young Kyoon Kim; Hwa Sik Moon
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

Review 6.  Current tools available for the diagnosis of drug-resistant tuberculosis.

Authors:  Christopher Gilpin; A Korobitsyn; K Weyer
Journal:  Ther Adv Infect Dis       Date:  2016-10-14

7.  A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.

Authors:  Elena Y Nosova; Danila V Zimenkov; Anastasia A Khakhalina; Alexandra I Isakova; Ludmila Y Krylova; Marina V Makarova; Ksenia Y Galkina; Maria A Krasnova; Svetlana G Safonova; Vitaly I Litvinov; Dmitry A Gryadunov; Elena M Bogorodskaya
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

8.  Frequency and Type of Disputed rpoB Mutations in Mycobacterium tuberculosis Isolates from South Korea.

Authors:  Kyung-Wook Jo; Soyeon Lee; Mi Ran Kang; Heungsup Sung; Mi-Na Kim; Tae Sun Shim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-07-03

9.  Pyrosequencing to resolve discrepant Xpert MTB/RIF and Mycobacterial Growth Indicator Tube 960.

Authors:  Kanchan Ajbani; Mubin Kazi; Jeffrey Tornheim; Swapna Naik; Rajeev Soman; Anjali Shetty; Camilla Rodrigues
Journal:  Lung India       Date:  2018 Mar-Apr

10.  Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.

Authors:  Pauline Lempens; Conor J Meehan; Koen Vandelannoote; Kristina Fissette; Pim de Rijk; Armand Van Deun; Leen Rigouts; Bouke C de Jong
Journal:  Sci Rep       Date:  2018-02-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.